Sales Milestone Payments Sample Clauses

Sales Milestone Payments. (a) With respect to each Collaboration Product, Novartis shall pay to Schrӧdinger each of the sales-based milestone payments set forth in Table 3 below (each, a “Sales Milestone Payment”) after the total annual Net Sales in a Calendar Year of such Collaboration Product in the Territory first achieves or exceeds the following specified thresholds (each, a “Sales Milestone Event”), it being understand and agreed, for clarity, that Sales Milestone Event #[**] and Sales Milestone Event #[**] are applicable only with respect to Collaboration Products Directed Against the [**], and Sales Milestone Payment #[**] and Sales Milestone Payment #[**] are each payable only following first achievement of the corresponding Sales Milestone Event by each Collaboration Product Directed Against the [**]. Such payments shall be noncreditable and nonrefundable. Such payments shall be noncreditable, nonrefundable and not subject to set-off. 1. [**] Dollars ($[**]) ● $[**] Dollars) if such Collaboration Product is directed to [**] Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to [**]Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to an [**] or its Replacement Collaboration Target 2. [**] Dollars ($[**]) ● $[**] Dollars) if such Collaboration Product is directed to [**] Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to [**]Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to an [**] or its Replacement Collaboration Target 3. [**] Dollars ($[**]) ● $[**] Dollars) if such Collaboration Product is directed to [**] Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to [**]Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to an [**] or its Replacement Collaboration Target 4. [**] Dollars ($[**]) ● $[**] Dollars) if such Collaboration Product is directed to [**] Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to [**]Target or its Replacement Collaboration Target ● $[**] Dollars) if such Collaboration Product is directed to an [**] or its Replacement Collaboration Target 5. [**] Dollars ($[**]) ● $[**] Dollars) if such Collaboration Product is directed to an [**] or its Replacement Collaborat...

Sales Milestone Payments. With respect to each of the First Antibody and the Subsequent Antibody, Pieris shall pay the following sales milestone payments to Enumeral by the later of (i) * days of the occurrence of * Product to achieve each of the following events and (ii) * days of the occurrence of the following events for any corresponding milestone payment with respect to any payment from Sublicensee to Pieris: Net sales threshold * Product * Product 1st year with Net Sales * * * 1st year with Net Sales * * * 1st year with Net Sales * * * Total * * Grand Total $67,500,000 (sixty seven million five hundred thousand dollars) For avoidance of any doubt, in no event shall milestone payments paid by Pieris under this Section 4.4 exceed $67,500,000 (sixty-seven million five hundred thousand dollars) for the First Antibody and $67,500,000 (sixty-seven million five hundred thousand dollars) for the Subsequent Antibody. Net Sales shall be calculated on a worldwide basis.

Sales Milestone Payments. Sublicensee will pay to Sublicensor the following non-refundable, one-time milestone payments as follows: (a) Within sixty (60) days following attainment of annual Net Sales in Japan equal to *****. (b) Within sixty (60) days following attainment of annual Net Sales in Japan equal to *****. (c) Within sixty (60) days following attainment of annual Net Sales in Japan equal to *****. For purposes of this Section 4.3, annual Net Sales shall be calculated on a calendar year basis. Nothing herein shall preclude multiple milestone payments from being paid in a given 12-month period if multiple milestones have been reached.

Sales Milestone Payments. As consideration to GEL for the rights granted to CPI under this Agreement, CPI shall pay to GEL a one-time payment in consideration of CPI’s achievement of each of the following Net Sales milestone events during the Term (each, a “Net Sales Milestone”): The First Time Annual Net Sales reach [***] [***] The First Time Annual Net Sales reach [***] [***] The First Time Annual Net Sales reach [***] [***] The First Time Annual Net Sales reach [***] [***] Annual Net Sales shall be measured for twelve month periods commencing on the Launch Date and ending on each anniversary of the Launch Date (“Net Sales Fiscal Year”). For each Net Sales Milestone achieved, CPI shall notify GEL in writing and promptly remit payment to GEL against the applicable Net Sales Milestone within forty-five (45) days after the achievement of same. CPI shall only be required to remit payment for one Net Sales Milestone in any calendar year. Accordingly, in the event more than one Net Sales Milestone is achieved in any Net Sales Fiscal Year, CPI shall remit payments in respect of such Net Sales Milestones as follows: Payment in respect of the first Net Sales Milestone achieved shall be remitted within forty-five (45) after the achievement of same; then, in the event a second Net Sales Milestone is achieved in such Net Sales Fiscal Year, then payment shall become due upon the later of (i) ninety (90) days following the achievement of such Net Sales Milestone or (ii) the fifth business day of the following calendar year; then, in the event a third Net Sales Milestone is achieved in such Net Sales Fiscal Year, payment in respect of such Net Sales Milestone shall become due upon the fifth business day of the calendar year after the payment described in (ii) becomes due. The maximum amount payable to GEL under this section is [***] over the Term of the Agreement.

Sales Milestone Payments. Subject to Section 10.8.4, on a Licensed Target-by-Licensed Target basis, Novartis will make one-time payments of each of the sales milestone payments indicated below (each, a “Sales Milestone Payment” and together with the Developmental Milestone Payments, the “Milestone Payments”) to Surface when aggregate Annual Net Sales of all Licensed Products for such Licensed Target in the Territory in a given Calendar Year first reach the dollar values indicated on each table below for the applicable T1 Licensed Products, Global Licensed Products or Regional Licensed Products (each, a “Sales Milestone Event”). Notwithstanding any other provision of this Agreement, each series of Sales Milestone Payments will be payable only once with respect to the specified Licensed Target, notwithstanding the number of Licensed Products (or the number of times a Licensed Product) may achieve the applicable Sales Milestone Event.

Sales Milestone Payments. As additional consideration for the rights granted to Indivior herein, Indivior shall pay to Addex a one-time milestone payment upon first achieving each of the Annual Net Sales thresholds set forth below (“Sales Milestone Payments”). For the avoidance of doubt, each Milestone Payment shall be payable one-time only upon the first occurrence of the event triggering the respective milestone provided below. First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] First time Annual Net Sales exceed [***] [***] Total [***]

Sales Milestone Payments. 14 7.4 Royalties .................................................. 14 7.5 Manner and Place of Payment ................................ 15 7.6 Records and Audit of Sales and Expenses .................... 15 ARTICLE 8. CONFIDENTIALITY ............................................ 16

Sales Milestone Payments. 6.5.1 Subject to Section 6.5.2, in consideration for Nucryst agreeing to grant S&N a license for the use in the manner specified in this Agreement of the Nucryst Technology and in addition to the royalties provided for in Section 6.1 and the event milestone payments provided for in Section 6.4, S&N shall pay to Nucryst the following sales milestone payments within fifteen (15) days of achieving each such sales milestone: 6.5.1.1 five million dollars ($5,000,000) upon Net Sales in any four (4) consecutive calendar quarters for all Products in the Territory exceeding for the first time [***]; 6.5.1.2 five million dollars ($5,000,000) upon Net Sales in any four (4) consecutive calendar quarters for all Products in the Territory exceeding for the first time [***]; 6.5.1.3 five million dollars ($5,000,000) upon Net Sales in any four (4) consecutive calendar quarters for all Products in the Territory exceeding for the first time [***]; 6.5.1.4 [***] upon Net Sales in any four (4) consecutive calendar quarters for all Products in the Territory exceeding for the first time [***]; 6.5.1.5 [***] upon Net Sales in any four (4) consecutive calendar quarters for all Products in the Territory exceeding for the first time [***]; and 6.5.1.6 [***] upon Net Sales in any four (4) consecutive calendar quarters for all Products in the Territory exceeding for the first time [***]. For clarification, each of S&N’s sales milestone payments identified in this Section 6.5 shall be made only once for the stated sales milestone triggering event. However, more than one (1) sales milestone may be achieved in a particular four consecutive quarter time period, in which case (if not previously paid) each such sales milestone payment shall be made by S&N to Nucryst. All sales milestone payments made by S&N under this Section 6.5 are non-refundable to S&N. 6.5.2 The sales milestone payments provided for in Section 6.5.1 shall be apportioned between Canada, the United States, and the remaining countries in the Territory based on the ratio that Net Sales in Canada, the United States, and the remaining countries in the Territory, as applicable, for such Products bear to Net Sales for all countries in the Territory and shall be paid in the same manner as the royalties specified in Section 6.1.

Sales Milestone Payments. (a) U.S. Events. AstraZeneca shall make each of the sales milestone payments indicated below to FibroGen when aggregate Annual Net Sales of all Products across all indications in the U.S. (other than sales by FibroGen in indications independently developed by FibroGen pursuant to Section 3.3(b) for which AstraZeneca does not opt in) first reach the Dollar values indicated below. Each milestone in this Section 8.5(a) shall be paid only once.